Antibodies that inhibit the enzyme activity of CD38 could help modulate the microenvironment of MM by preventing the conversion of pro-inflammatory NAD+ to immunosuppressive adenosine [3,37,50,51]. The gene discussed is CD38; the disease is Miyoshi myopathy.